NovoCure (NVCR) director sells 2,945 shares to cover RSU tax

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

NovoCure Ltd director Vernon W. Anthony reported an open-market sale of 2,945 Ordinary Shares of NovoCure on June 2, 2026 at a weighted average price of $15.7707 per share. According to the footnotes, these shares were sold to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and did not represent a discretionary trade. After this transaction, Anthony directly holds 197,657 Ordinary Shares, indicating the sale was a small, routine adjustment for tax purposes rather than a significant change in his overall position.

Insider Trade Summary

Net Seller: 2,945 shares ($46,445)

Net Sell 1 txn

Insider VERNON W ANTHONY

Role null

Sold 2,945 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,945	$15.7707	$46K

Holdings After Transaction: Ordinary Shares — 197,657 shares (Direct, null)

Footnotes (1)

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.

Key Figures

Shares sold: 2,945 shares Weighted average sale price: $15.7707 per share Shares held after transaction: 197,657 shares +1 more

4 metrics

Shares sold 2,945 shares Open-market sale on June 2, 2026 to cover tax withholding

Weighted average sale price $15.7707 per share Ordinary Shares sold in multiple trades between $15.65 and $15.88

Shares held after transaction 197,657 shares Director’s direct NovoCure Ordinary Share holdings post-transaction

Execution price range $15.65–$15.88 per share Range of prices for multiple trades comprising the reported sale

Key Terms

Restricted Stock Units, tax withholding obligations, sell to cover, equity incentive plans

4 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to cover tax withholding obligations in connection with the vesting"

sell to cover financial

"to be funded by a "sell to cover" transaction and does not represent"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"under its equity incentive plans to require the satisfaction of tax"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VERNON W ANTHONY

(Last)

(First)

(Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/02/2026		S		2,945⁽¹⁾	D	$15.7707⁽²⁾	197,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Vernon, W. Anthony	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NovoCure (NVCR) director Vernon W. Anthony report?

Director Vernon W. Anthony reported selling 2,945 NovoCure Ordinary Shares at a weighted average price of $15.7707. The sale occurred on June 2, 2026 and was linked to equity compensation tax withholding, not a discretionary portfolio decision.

Why did Vernon W. Anthony sell NovoCure (NVCR) shares in this Form 4 filing?

The filing states the shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units. NovoCure’s equity incentive plans mandate a “sell to cover” transaction for these taxes, so the sale was mechanical rather than a discretionary trade.

How many NovoCure (NVCR) shares does Vernon W. Anthony hold after this transaction?

After selling 2,945 Ordinary Shares, Vernon W. Anthony directly holds 197,657 NovoCure shares. This indicates the transaction was small relative to his overall position, functioning mainly as a tax-related adjustment for vested equity awards.

At what price were the NovoCure (NVCR) shares sold in this insider transaction?

The reported weighted average sale price was $15.7707 per NovoCure Ordinary Share. The filing notes the transaction was executed in multiple trades within a price range from $15.65 to $15.88, resulting in that weighted average price disclosure.

Was the NovoCure (NVCR) insider sale by Vernon W. Anthony discretionary?

The filing explicitly states the sale did not represent a discretionary trade. It was required under NovoCure’s award agreement, which mandates a “sell to cover” transaction to fund tax withholding obligations arising from Restricted Stock Unit vesting.

What type of compensation event triggered the NovoCure (NVCR) sell-to-cover transaction?

The sale was triggered by the vesting of Restricted Stock Units granted under NovoCure’s equity incentive plans. When these RSUs vested, the company required a sell-to-cover transaction to satisfy related tax withholding obligations, prompting the 2,945-share sale.